A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus(SELINA Study)
Latest Information Update: 30 Jul 2021
At a glance
- Drugs Linagliptin (Primary) ; Antihypoglycaemics; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms SELINA
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 15 Nov 2017 Status changed from active, no longer recruiting to completed.
- 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Nov 2012 Planned initiation date changed from 1 Oct 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.